Naringin has been reported to reduce lipid synthesis by reducing the hepatic expression of several proteins involved in the DNL pathway, such as SREBP-1, ACC and FAS in mice fed a high-fat diet (Pu et al., 2012), diabetic rats fed a high-fat diet (Kumar Sharma et al., 2011), alcoholic fatty liver disease in rats (Zhou et al., 2019) and in obese C57BL/6J mice (Mu et al., 2020). Here, SREBF1 is linked to alcoholic fatty liver disease.